Dong Yujie, Zhou Lijuan, Wang Jinghui, Cai Yiran, Mu Jing, Zhang Haiqing
Department of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2015 Jun;37(6):436-40.
To analyze the clinicopathological characteristics of patients with anaplastic lymphoma kinase (ALK) rearrangements in lung adenocarcinoma, and the clinical therapy and prognosis of the patients.
Clinicopathological data of 34 cases of ALK-positive patients treated in the Beijing Chest Hospital from 2005 to 2014 were reviewed. The expression of ALK proteins in the resected tumors was detected by immunohistochemistry, and EGFR mutations were examined by polymerase chain reaction and a direct DNA sequencing method.
Among the 34 patients, 20 were male and 14 were female, the median age was 49, and 11 were smokers and 23 were never smokers. The clinical stages of the patients were stage IA in 5 patients, IB in one patient, IIA in two patients, IIIA in 16 patients, IIIB in 5 patients, IV in 4 patients, and one patient of unknown stage. ALK-positive tumors showed strong granular staining in cell cytoplasm by immunohistochemistry. Forteen patients were solid predominant subtype with mucin production, 10 of acinar predominant subtype, 6 of papillary predominant subtype, 3 of micropapillary predominant subtype, and one was of colloid variant. There were 18 cases with mucin production, 6 cases had signet-ring cell morphology, and 10 cases showed cribriform pattern. Only one patient had coexistence of ALK rearrangement and EGFR mutation (L858R at exon 21). Of the 34 patients, 24 patients were followed up. The median follow up of the 24 patients was 11.0 months (1.7-48.7 months).
ALK-positive tumors as a molecular subtype of lung adenocarcinoma have distinct clinicopathological features. The histological findings of ALK-positive tumors are characterized by solid predominant subtype with mucin production, acinar predominant subtype, signet-ring cells and cribriform structures. They were rarely co-mutated with EGFR mutation.
分析肺腺癌中间变性淋巴瘤激酶(ALK)重排患者的临床病理特征以及患者的临床治疗和预后情况。
回顾性分析2005年至2014年在北京胸科医院接受治疗的34例ALK阳性患者的临床病理资料。采用免疫组织化学法检测切除肿瘤中ALK蛋白的表达,通过聚合酶链反应和直接DNA测序法检测表皮生长因子受体(EGFR)突变情况。
34例患者中,男性20例,女性14例,中位年龄49岁,吸烟者11例,从不吸烟者23例。患者临床分期:IA期5例,IB期1例,IIA期2例,IIIA期16例,IIIB期5例,IV期4例,1例分期不明。ALK阳性肿瘤免疫组织化学显示细胞质呈强颗粒状染色。实性为主型伴黏液分泌14例,腺泡为主型10例,乳头为主型6例,微乳头为主型3例,胶样变型1例。有黏液分泌18例,印戒细胞形态6例,筛状结构10例。仅1例患者同时存在ALK重排和EGFR突变(第21外显子L858R)。34例患者中,24例进行了随访。24例患者的中位随访时间为11.0个月(1.7 - 48.7个月)。
ALK阳性肿瘤作为肺腺癌的一种分子亚型具有独特的临床病理特征。ALK阳性肿瘤的组织学表现以实性为主型伴黏液分泌、腺泡为主型、印戒细胞和筛状结构为特征。它们很少与EGFR突变同时发生。